Constipation News and Research

Latest Constipation News and Research

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

28 Oct 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

Oxytocin treatment improves social, emotional and behavioral problems among young kids with autism

A five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.

27 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.

22 Oct 2015

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

19 Oct 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Loyola gastroenterologist provides tips to IBS patients for healthy living

More than 20 percent of the US population lives with irritable bowel syndrome (IBS) and for many Americans it is an ongoing challenge. But when it comes to treatment, old advice from Mom was right. Often, the key is to eat right and go outside and play.

16 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Laboratories, LLC ("Commonwealth") announced today that it has formed an agreement with Quest Diagnostics ("Quest") that will expand the availability of IBSchek™, a new laboratory developed blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS).

From Quest Diagnostics 15 Oct 2015

AGS releases updated, expanded Beers Criteria to improve medication use in older adults

The American Geriatrics Society today released its second updated and expanded Beers Criteria--lists of potentially inappropriate medications for older adults who are not receiving hospice or palliative care, and one of the most frequently cited reference tools in the field of geriatrics.

12 Oct 2015

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

11 Oct 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Gut microbiome can play significant role in the body's response to gluten

Investigators interested in celiac disease, a chronic gastrointestinal disorder caused by an immunologic response to the ingestion of gluten, have wondered why only 2% to 5% of genetically susceptible individuals develop the disease.

8 Oct 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

Study evaluates effectiveness of hypnotherapy

Although hypnosis has existed for hundreds of years, today it is still difficult to clearly judge its usefulness in the medical domain.

10 Sep 2015

Constipation News and Research

Latest Constipation News and Research

Lilly, Merck expand oncology clinical trial collaboration

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Oxytocin treatment improves social, emotional and behavioral problems among young kids with autism

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

FDA grants accelerated approval to Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Loyola gastroenterologist provides tips to IBS patients for healthy living

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

Commonwealth Lab expands access to new IBS test with national agreement with Quest

AGS releases updated, expanded Beers Criteria to improve medication use in older adults

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Gut microbiome can play significant role in the body's response to gluten

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

Study evaluates effectiveness of hypnotherapy

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Constipation News and Research

Latest Constipation News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in